Multisystem Inflammatory Syndromes in Pediatric Populations

Multisystem inflammatory syndromes in children represent a rare but serious post-infectious hyperinflammatory condition most notably observed in association with SARS-CoV-2. Clinically, affected children present with persistent fever, gastrointestinal disturbance, mucocutaneous involvement and cardiovascular compromise. Laboratory profiles are characterised by elevated markers of systemic inflammation, including C-reactive protein, ferritin and D-dimer, alongside lymphopenia and coagulopathy. Cardiac manifestations range from myocardial dysfunction and arrhythmias to coronary artery abnormalities, mirroring features of Kawasaki disease and toxic shock syndrome. Although initial reports linked cases to acute viral infection, emerging evidence implicates delayed host immune dysregulation, autoantibody production and superantigen-like activation of T cells. Management has largely relied on immunomodulatory strategies centred on intravenous immunoglobulin, corticosteroids and targeted biologics. Despite rapid clinical improvement in most patients, the potential for long-term sequelae of vascular or myocardial injury underscores the need for vigilant follow-up and a deeper understanding of pathogenesis to inform prophylaxis and treatment.

Research from Nature Portfolio

Recent mechanistic studies have illuminated molecular pathways that bridge viral exposure and autoimmunity. One investigation identified a shared epitope between a host endosomal protein and the viral nucleocapsid, demonstrating that children with post-infectious inflammation generate cross-reactive antibodies and T cells that recognise both self and viral targets. This finding offers a direct link between infection and breakdown of tolerance, suggesting a role for molecular mimicry in driving systemic inflammation. In parallel, single-cell multi-omics analyses have dissected the innate and adaptive landscape of acute presentation. These studies reveal an expansion of a distinct T-cell receptor Vβ21.3+ subset alongside enhanced interleukin-18 production from monocytes and natural killer cells. Upregulated CD95 (Fas) signalling and skewing of helper T-cell differentiation towards pro-inflammatory phenotypes have been implicated as central mediators of tissue injury, illustrating cooperative pathways of innate cytokine release and superantigen-like T-cell activation in disease pathogenesis.

Multisystem Inflammatory Syndromes in Pediatric Populations publication trend

The graph below shows the total number of articles in multisystem inflammatory syndromes in pediatric populations across all publications each year (not limited to Nature Index journals).

Technical terms

Multisystem inflammatory syndrome in children (MIS-C): A post-infectious hyperinflammatory condition affecting multiple organs, often following SARS-CoV-2 infection.

Molecular mimicry: An immunological phenomenon whereby structural similarity between pathogen and host proteins leads to cross-reactive immune responses.

Superantigen: A class of antigens that elicit extensive T-cell activation by bridging T-cell receptors and major histocompatibility complexes outside conventional antigen-binding sites.

Intravenous immunoglobulin (IVIG): A pooled preparation of human antibodies used to modulate immune responses in inflammatory and autoimmune disorders.

Interleukin-6 and interleukin-1 blockade: Targeted biologic therapies that inhibit key pro-inflammatory cytokines to attenuate systemic inflammation.

T cell receptor Vβ21.3+ subset: A distinct T-cell population identified by its variable beta-chain usage, implicated in oligoclonal expansion during hyperinflammatory responses.

References

1. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (2020).
2. Molecular mimicry in multisystem inflammatory syndrome in children. Nature (2024).
3. Enhanced CD95 and interleukin 18 signalling accompany T cell receptor Vβ21.3+ activation in multi-inflammatory syndrome in children. Nature Communications (2024).
4. Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study. The Lancet Rheumatology (2023).
5. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health (2024).
6. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19. Science Immunology (2021).